TVTX241220P5000
- 0.10
- 0.000.00%
Travere Therapeutic Newsroom
In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
Insider Sale: SVP of $TVTX (TVTX) Sells 12,090 Shares
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Travere Therapeutics (TVTX) Gets a Buy From J.P. Morgan
Express News | Travere Therapeutics Inc : JP Morgan Cuts Target Price to $42 From $43
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Travere Therapeutics Is Maintained at Neutral by Piper Sandler
Piper Sandler Maintains Travere Therapeutic(TVTX.US) With Hold Rating, Raises Target Price to $22
Piper Sandler Reaffirms Their Hold Rating on Travere Therapeutics (TVTX)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Travere Therapeutics Expects Gross Proceeds to Be $125M>TVTX
Travere Therapeutics Offering Expected to Close on Nov. 12>TVTX
Travere Therapeutics Announces Proposed Public Offering of Common Stock
TD Cowen Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $20
Travere Therapeutics to Present at Upcoming Investor Conferences
Travere Therapeutics Is Maintained at Sector Outperform by Scotiabank
Travere Therapeutics Price Target Raised to $27.00/Share From $23.00 by Scotiabank
Express News | Barclays Maintains Overweight on Travere Therapeutics, Raises Price Target to $20